3 results
Approved WMOCompleted
Primary To test the hypothesis that at least 1 dose of LY2951742 (120 mg or 240 mg/month) is superior to placebo in the prevention of migraine headache in patients with chronic migraineKey Secondary Objectives If LY2951742 (120 or 240 mg/month) is…
Approved WMORecruiting
The primary objective of the study is to evaluate the efficacy and safety and rIFN-γ as adjunctive treatment in combination with standard therapy for the treatment of patients with candidemia. Efficacy is defined as clearance of candidemia within…
Approved WMORecruiting
To determine B-cel en T-cel immunity im COVID-19 patients